Panakeia is building a universal engine for one step precision cancer diagnosis. Our deep learning technologies provide complete diagnosis information at the fraction of cost and time that work everywhere around the world therefore democratizing cutting edge cancer diagnosis for all. 

The company is the future of women’s health. Hertility Health is a machine learning-driven healthcare solution which integrates both a symptom checker and biomarker testing, delivered to the door. We tailor each woman’s individual biometric panel by taking into account her reproductive and medical history. We therefore, ensure the route-to-diagnosis and care is accurate, accessible and affordable. 

Identified a novel method of sourcing human cells, that will allow for unlimited and unprecedented access to stem cell-like cells. Developing the necessary tools for collection to source cells from anyone. This will allow for unrestricted access to rare disease patients, children and other patients. Allowing for an abundance of precious material, that will accelerate research into our own biology. Bringing personalised medicine within reach.

Recent successes

  • Formed a new collaboration with UCL and Great Ormond Street Hospital.
  • Collaborative grant proposal to Kidney Research UK has recently been submitted.
  • Corporate collaboration with JEB Engineering to further develop and manufacture the product.
  • Through R&D new IP has been created with patent filing pending.
  • First visual prototypes have now been manufactured.

CC Bio use a data driven, synthetic biology approach to produce smart therapeutics capable of preventing microbiome dysbiosis before disease is detected or manifests. They are starting with Bacterial Vaginosis ($3.6B combined USA/European symptomatic and asymptomatic market per annum) as their first indication. They seek a seed round of $3.2 million/£1mil to reach Phase 1 completion of their BV therapeutics and fully automate their smart therapeutic discovery platform for other therapeutic indications 



Recent successes

  • Winning the Accelerate@abraham competition2019 and awarded InnovateUK funding in partnership with Brunel University for the for continued R&D into the Bacterial Vaginosis programme.

  • Recently hired to continue the development of the automated therapeutic discovery platform. 

  • £1m seed investment round recently opened which is scheduled to close Q2 2020. This will be to accelerate the development of live bacterial therapeutics for target indication (Bacterial Vaginosis, Acne and Oral Health), culminating in an IND filing for Bacterial Vaginosis in 2021. The investment will also allow full implementation of their automated therapeutic discovery platform.


ConcR’s mission is to reduce treatment resistance in cancer, by enabling superior targeting of treatment in trials and clinical practice. ConcR predicts the evolution of cancer in order to identify optimal, treatment for an individual, reduce treatment resistance, proactively adapt treatment before it becomes ineffective. 

Limbic are bringing quantifiability to mental health. Depression and anxiety cost the global economy $1 trillion each year. But health services are struggling to deal with the problem. Unlike other areas of medicine, mental health professionals rely entirely on their patients for the information they need to diagnose and treat. Using an AI-powered patient reporting platform, Limbic makes it easier than ever for patients to provide their therapist with high-quality data.

Recent successes

  • Further development of patient mobile app
  • Further development of clinician web dashboard
  • Raised investment on 2 convertible notes ahead of the next round
  • Awarded an Innovate UK grant
  • Made 3 new hires to grow the team to 9 people
  • Presented our wearable emotion detection AI at a machine learning conference in Cambridge
  • 17 psychotherapy clinics signed up to use Limbic upon release
The Vine Health digital platform optimises the care of cancer patients through a mobile app that incentivises easy tracking of symptoms, side effects and medications, automatically integrating this with lifestyle data from smartphones and wearable devices. Machine learning is used to deliver highly personalised behavioural interventions and bespoke evidence-based educational/support material, supporting highly engaged patient self-management during and after treatment. There is strong evidence that the tracking alone increases tolerance of chemotherapy and improves outcomes. Through the platform, Vine Health is able to accurately track high-quality patient-reported outcome and real-world data along evidence-based scales in real-time to support health service delivery, drug development and research.

  • Launching mobile app in January, available to support all those with cancer who want to feel more in control of their health.
  • In 2019, raised a seed round and grown to a team of 6.
  • Named ‘Global Healthcare Startup of the Year’ by the World Healthcare Journal and ‘Most Innovative Startup of the Year’ by Deloitte.
  • Working with providers and commercial partners to ensure that the app is available for free to patients.

ThinkSono is a cutting edge Ultrasound AI company. They have built the first product in the world to detect deep vein thrombosis (DVT).” DVT is the number one cause of preventable hospital death and is responsible for more deaths than breast cancer, prostate cancer, AIDS and car accidents, combined.

Recent successes

  • Finalised the AutoDVT software prototype

  • Clinical trial documentation finalised as part of an ongoing trial

  • A new investment round has opened.

  • Partnership discussions with the largest ultrasound companies in the world

Better early detection and diagnosis of bowel cancer for patient specific surveillance protocols. CADDIE: using AI and space technology to automatically detect and classify polyps in colonoscopy videos. 

Recent successes

  • Awarded funding from InnovateUK, European Space Agency, Horizon 2020, The Royal Society, The Royal Academy of Engineering and the IPO.

  • Established Software2.0 machine learning pipeline for highly scalable deep learning applications and deployed cloud based live video image processing prototypes.

  • Established QMS and developed our regulatory strategy.

  • Created partnerships with a number of hospitals and established endoscopy companies with more in the pipeline.

  • Next year, deploying our cloud based real time healthcare product to a multi centre clinical trial and continued development of our explainable artificial intelligence solution supported by the Royal Society.

Motilent is a medical imaging analysis company that is “changing the way we see the gut”. Specifically we work in the area of magnetic resonance imaging (MRI) for gastrointestinal disorders, the most exciting part of our work is our market cleared medical device product GIQuant for use in patients with Crohn’s Disease.

Recent successes

  • Successful procurement and signed for the first clinical installation. In conversations with six large hospitals to start trialling the software in Q1 2020.

  • Collaborating with Great Ormond Street Children’s Hospital to benchmark performance of GIQuant technology non-invasively to grade Crohn’s disease in children showing excellent agreement with the endoscopic biopsy gold standard.

  • Recently signed a licensing deal with a major distribution partner taking the technology to 70% of clinics in North America.

  • Appointed a CTO from Microsoft’s Medical Imaging division to help build and scale the technology as it enters the clinic and undergoes FDA assessment.

Lifebit democratises muti-omics, biomedical & big data analysis with its federated system and provides AI solutions that can reason about these data like humans do. This enables developers& researchers, regardless of their computational & data analysis training level, as well as their organisations (i.e. pharma, biotech, research), to instantly run & scale such analysis in a cost-speed-efficient and reproducible way that automates the analysis processes, learns from the data, and provides impactful insights.

Recent successes

  • In the last 6 months, Lifebit has closed contracts with Boehringer Ingelheim, GSK, The Jackson Laboratory, and several direct-to-consumer genomics companies.

  • We have engagement with all of the top 10 pharma companies, and our current sales pipeline is valued at over $20M.

  • Lifebit’s core product is evolving quickly due to co-development with our partners including Genomics England, the Sanger Institute, and AstraZeneca. The platform is now enabling users to run containerised and bioinformatics workflow-system analysis pipelines, interactive analysis & visualisations with Jupyter notebooks & IGV (Interactive Genome viewer) & have advanced data management, as well as, multi-cloud & HPC support all in one single place without ever needing to leave the platform.

  • The Lifebit AI-Engine continues to be a hot topic with big pharma because of its ground-breaking applications in drug discovery & development, around target identification & validation, drug repurposing and immune profiling.

  • Before the end of 2019, we will continue to get more DTC genomics companies onto the platform and deliver across key deals, with the objective to close more pharma and research clients. Technically, we will be delivering GCloud integration and continuing to expand our marketplace offering.

  • We are starting our Series A fundraising.